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Beta-caryophyllene (BCP) and docosahexaenoic acid (DHA) are components of several plants with documented anti-inflammatory
and analgesic effects in animal pain models. In the present study, in vitro and in vivo tests were carried out to evaluate their effects,
alone or in combination, during long-lasting administration in a model of persistent pain. IR spectra of the two compounds were
obtained to determine their chemical stability and then in vitro toxicity was evaluated in fibroblasts and astrocytes. In the in vivo
tests, the analgesic effects of BCP and BCP+DHA were determined in male rats subjected to a model of persistent recurrent pain
(three repetitions of the formalin test once a week) tomimic recurrent pain. Both substances were administered per os in almond oil
for 2 weeks. Gonadal hormones were determined at the end of the tests to evaluate treatment-induced effects on their levels. BCP
changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration.
In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and
2 weeks of treatment. Estradiol and testosterone levels were increased only in the BCP group. In conclusion, BCP alone or at lower
concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.
1. Introduction
Pain (especially chronic pain) has finally achieved worldwide
acceptance as a disease (and not only a symptom) with
huge personal and social costs. Epidemiological statistics are
alarming: in Europe, it is estimated that one in four adults has
a chronic pain condition; in the US, it is believed that at least
38million adults suffer from chronic pain [1]. For this reason,
many efforts have been made in scientific and administrative
circles to achieve acceptable, definitive solutions to chronic
pain. Nevertheless, patients too often remain inadequately
treated. Moreover, the beneficial effects of pain killers are
often accompanied by serious, long-lasting drug-induced
side effects [2].
The discovery of specific cannabinoid receptors (CB1
and CB2) [3] and their endogenous ligands [4] has led to
a better understanding of the pharmacological actions and
use of cannabinoids as therapeutic agents in various pain
conditions. CB1 receptors are widely distributed throughout
the central and peripheral nervous systems, and activation of
these receptors produces psychotropic effects [3, 4]. Instead,
CB2 receptors are expressed mainly by immune cells, act
in the periphery and do not show psychotropic effects [5–
7]. When activated, CB2 receptors can affect the release of
chemical messengers (i.e., cytokines by immune cells) and
can modulate immune cell trafficking ([7–11] for reviews).
In both clinical and preclinical studies, cannabis has been
shown to have analgesic effects at central and peripheral levels
[12, 13].
Cannabinoid receptor ligands such as beta-caryophyllene
(BCP, a FDA-approved food additive) selectively bind to
peripheral cannabinoid receptors (CB2) and act as full ago-
nists [14]. BCP has been shown to have multiple functions.
In particular, it had strong anti-inflammatory and analgesic
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effects in rats and mice [14–16] in a model of acute single
administration.
The omega-3 PUFAs eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) (found in salmon and sea-
weed) have well-known beneficial activities. After being
enzymatically converted into bioactive autacoids, they have
inflammation-resolving properties [17]. It was recently
reported that deficiencies in these PUFAs are linked to
chronic inflammatory disease [17]. Once converted to bioac-
tive metabolites, EPA and DHA are needed to resolve the
inflammation acting through resolvins, natural endogenous
regulators of the immune system. For these reasons, a possible
synergistic effect of the combination of BCP and DHA on
the modulation of inflammatory pain responses was assessed
in the present study. First, we determined if BCP and DHA
would chemically interact when mixed together; second, we
evaluated the in vitro acute toxicity of BCP and DHA alone
and in combination at different concentrations; third, we
assessed whether the administration of BCP or BCP plus
DHA would affect pain behaviour in a model of persistent
pain, the formalin test; fourth, we used the determination of
gonadal hormones to evaluate other possible effects induced
by long-lasting administration of these substances.
2. Methods and Materials
2.1. Substances. Beta-caryophyllene (BCP), a natural bicyclic
sesquiterpene present in many essential oils, has the formula
as in Figure 1.
Docosahexaenoic acid (DHA), a long-chain essential fatty
acid belonging to the omega-3 family, has the formula as in
Figure 2.
2.2. Evaluation of Chemical Stability. Thechemical stability of
the two substances was analysed to determine if they would
interact when mixed together. The IR spectra of BCP and
DHA were obtained pure and in two mixtures with an FTIR
Nicolet 5700-ThermoSpectrometer using anATR (attenuated
total reflectance) cell for liquids equipped with Ge crystal at
45∘. The spectra (156 scans) were recorded at a resolution of
4 cm−1 using anMCT (mercury cadmium telluride) detector.
Dry N
2
was circulated in the cell to eliminate the CO
2
and
humidity in the air.
2.3. In Vitro Studies
2.3.1. Materials for Cell Culture. Dulbecco’s Modified Eagle’s
Medium (DMEM), trypsin solution, and all the solvents
used for cell culture were purchased from Lonza (Belgium).
Mouse immortalized NIH3T3 fibroblasts were obtained from
American Type Culture Collection (USA). HumanU373-MG
astrocytes (deriving from a human astrocytoma line) were
kindly provided by Professor Giampaolo Pessina (University
of Siena).
2.3.2. Procedures. Both cell lines were propagated in DMEM
supplemented with foetal bovine serum at 10%, L-glutamine-
streptomycin at 1%, and nonessential amino acids at 1%
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and incubated at 37∘C in an atmosphere containing 5%
CO
2
. At confluence, the cells were washed with PBS 0.1M,
detached from the support by means of a trypsin solution,
centrifuged at 1500 rpm for 5 minutes at room temperature,
and resuspended in complete medium (dilution 1 : 15). 15,000
cells suspended in complete medium were seeded in each
well of a 24-well multiwell; the medium volume of each well
was brought to 1mL and the cells were left in an incubator
at 37∘C and 5% CO
2
for 24 hours. At the end of incubation,
dilutions of BCP and DHA were added to each sample and
the multiwells were left to incubate for a further 24 hours at
37∘C and 5% CO
2
. Each dilution of each sample was tested in
8 replications.
2.3.3. Evaluation of Acute Toxicity. Toxicity was evaluated by
determining the cell viability after 24 hours of incubation
with BCP and DHA with the neutral red uptake (NRU)
method according to the procedure of the National Toxi-
cology Program (NTP) Interagency Center for the Evaluation
of Alternative Toxicological Methods (NICEATM). The
concentrations of BCP tested with both cell types, alone
or mixed with DHA, were 1 × 10−2, 1 × 10−4, 1 × 10−6,
1 × 10
−8,1 × 10−10 and 1 × 10−12M. The concentrations of
DHA, used alone or in combination with BCP, were 3.5,
3.5 × 10
−2, 3.5 × 10−4, 3.5 × 10−6, 3.5 × 10−8, and
3.5 × 10
−10%.
First, the following solutions were prepared:
(1) stock solution of neutral red: 0.33 g of neutral red in
100mL of sterile distilled water;
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(2) medium with neutral red: 1.0mL of stock solution +
99.0mL of complete culture medium;
(3) neutral red extraction solution: glacial acetic acid at
1% + ethanol at 50% + distilled water at 49%.
At the end of the incubation period, the culture medium
was removed from each well and the cells were gently washed
with 1mL of PBS preheated to 37∘C.Thewashing solutionwas
removed and 1.0mL of medium with neutral red was added
to each well. The multiwells were placed in an incubator
for 3 hours. At the end of the incubation time, the medium
with neutral red was removed, each well was washed with
1mL of PBS preheated to 37∘C and exactly 1mL of extraction
solution was added to each well. At this point, the plates were
placed on a shaker for 20–45 minutes at room temperature
in order to extract the dye from the vital cells. During this
phase, the plates were covered to protect them from light. Five
minutes after the end of the shaking, the extraction solution
was removed from each well and the absorbance was read at
540 nm in a UV/Vis spectrophotometer (Lambda 25, Perkin
Elmer).
2.4. In Vivo Study. The in vitro acute toxicity study showed
that BCPwas toxic at high concentration, although its toxicity
was completely reversed by concomitant DHA administra-
tion. Therefore, it was necessary to evaluate if the in vivo
BCP analgesic activity would be maintained at a lower dose
with the collaboration of a “safe” compound like DHA.
The following groups were used to study the behavioural
and hormonal responses to long-lasting treatment with BCP
alone or in combination with DHA: group BCP, receiving
BCP alone (5mg/Kg/day), and group BCP+DHA, receiving
half of the dose of BCP (2.6mg/Kg/day, 52%) plus DHA
(2.4mg/Kg/day, 48%), with the OIL group receiving sweet
almond oil as control. These doses were chosen following
suggestions in the literature [14, 18, 19].
2.4.1. Subjects. Twenty-four male Wistar Han rats were used
(225 gr upon arrival). Throughout the experiment, the rats
were kept in groups (4 per cage) with ad libitum access
to food and water on a 12 h light/dark cycle with lights on
at 7 pm. The experimental phases started one week after
the arrival of the animals to allow them to habituate. All
experimental procedures were carried out during the active
phase of the animal’s circadian cycle (10.00–12.00 am) in
dedicated rooms provided with red light and white noise.The
regulations of the European Communities Council Directive
86/609/EEC and the ethical guidelines for the study of
experimental pain in conscious animals [20] were followed in
all experimental phases. Permission from the ItalianMinistry
of Health (Ministero della Sanita`) was obtained.
2.4.2. Experimental Procedures. As described in Figure 3,
the animals were subjected to the analgesimeter (Anal 1)
and formalin (FT1) tests before the beginning of substance
treatment to evaluate the basal response of each one to
the different experimental procedures. One week and two
weeks after daily administration of the test substances,
the animals were subjected to the second and third anal-
gesimeter and formalin tests (Analg 2, FT2, Analg 3, and
FT3, resp.). Immediately after the last formalin test (FT3), all
animals were sacrificed.
Analgesimeter Test. This test was carried out to evaluate
the phasic, mechanical paw-withdrawal threshold of awake,
lightly restrained rats. The apparatus (Analgesimeter, Ugo
Basile, Italy) applies a linearly increasing force to the dorsum
of the rat’s hind paw, resulting in the nociceptive flexion
reflex. Each test consisted in two measurements in the right
and left paws, with 15 minutes in between. They were carried
out the day before the formalin test. The latency to paw-
withdrawal was recorded and subsequently analysed.
Formalin Test. On the day of the experiment, the animals were
transported to the experimental room and gently restrained
and injected with formalin (FT), after which they were
immediately placed in the open-field apparatus where their
behaviour was videotaped for 60min for subsequent analysis.
Thefirst treatmentwith formalin (FT1, 50𝜇L, s.c. in the dorsal
right hind paw) was carried out at a concentration of 2.5%
to induce a moderate but persistent inflammatory state. The
second (FT2) and third (FT3) formalin treatments involved
injection of the same amount of formalin (50 𝜇L) but at a
very low concentration (1%) merely to induce spontaneous
pain responses. This procedure was chosen because of the
strong similarity with clinical pain episodes (recurrent pain).
The formalin test was selected as the most relevant test
to assess pain intensity in unrestrained animals. Indeed
formalin injection induces a series of specific behaviour that
can easily be quantified: licking and tonic flexing of the
injected paw (measured in seconds) and paw jerk (phasic
flexion, measured as frequency). Nonpain-related behaviour
was also recorded as an index of motor activity: number
of seconds spent exploring the environment (activity) and
cleaning the body (self-grooming), number of times the
animal reared to explore the environment (rearing), and time
spent sitting alert or in sleeping-like posture (crouch).
At the end of each formalin test, the animals were
returned to their home cages.
After the first formalin test, all animals belonging to
the same cage were randomly assigned to the experimental
groups: group OIL (𝑛 = 8), group BCP (𝑛 = 8), and group
BCP+DHA (𝑛 = 8). The animals were treated by oral gavage
for 15 days (twice a day) until the end of the experimental
phases.
For increased objectivity and consistency, the behavioural
analysis was carried out by a trained technician blind to the
treatments.
Hormone Determination. Immediately after the third forma-
lin test (FT3), the animals were anaesthetized, the abdomen
was opened, and blood was collected from the abdomi-
nal vein in heparin-added syringes. Blood was centrifuged
(3000 g for 10min at 4∘C) to obtain plasma and the samples
were frozen at −20∘C until the assay. To determine possible
endocrine modulation by the treatments, we measured total
testosterone and estradiol plasma levels with the ADVIA
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Figure 3: Schematic representation of the experimental design. See Section 2 for details.
Centaur T assay, a competitive immunoassay using direct
chemiluminescent technology.The intra-assay and interassay
coefficients of variation were 5% and 8%, respectively, for all
determinations.
Data Analysis. The acute toxicity data were analysed by one-
way ANOVA with the factor Concentration (7 levels: control
and 6 scalar doses of BCP, DHA, and BCP+DHA).
The analgesimeter latencies were expressed as percentage
of variation recorded during the second and third tests with
respect to the first one, separately for the right and left paws;
analyses was carried out by one-way ANOVA with the factor
Treatment (3 levels: OIL, BCP, and BCP+DHA).
All behavioural data were analysed by ANOVA with the
factors Treatment (3 levels: OIl, BCP, and BCP+DHA) and
Time (60min, split into 12 periods of 5 minutes each) for
each formalin test. Moreover, to evaluate the modulation
of pain behaviour by treatments during the three formalin
tests, ANOVA was applied to the total of pain behaviour
recorded during the second phase (20–45min) with the
factors Treatment (3 levels: OIL, BCP, and BCP+DHA) and
Test (3 levels: FT1, FT2, and FT3). Hormonal data were
analysed by one-way ANOVA with the factor Treatment (3
levels: OIL, BCP, and BCP+DHA). The LSD post hoc test
was applied when appropriate. The criterion for statistical
significance was 𝑃 < 0.05.
3. Results
3.1. Chemical Stability. As shown in Figure 4, the IR spec-
tra of the two mixtures (BCP52%-DHA48% and BCP70%-
DHA30%) were exactly superimposable on the spectrum
obtained from the mathematical sum of the IR spectra of the
two pure components (BCD spectrum + DHA spectrum in
a ratio of 1 : 1). The infrared spectroscopy data allowed us to
rule out the formation of a BCP-DHA complex with its own
chemical identity. Hence, the structure and consequently the
biological activity of the two single compounds in themixture
were preserved, since they were not compromised by any
strong interaction involving the functional groups of the two
molecules.
3.2. Acute Toxicity. The in vitro acute toxicity of the following
compounds, as a function of their concentration, was tested:
BCP, DHA, and BCP+DHAmixture (52%–48%).
The graphs of cell vitality of NIH3T3 fibroblasts andU373
astrocytes in contact with the different concentrations of BCP,
BCP+DHA, and DHA are given below. At the higher concen-
trations, BCP showed significant toxic effects, as evident from
the lower vitality level in those preparations (Figure 5(a)).The
effect was greater on the fibroblasts than on the astrocytes.
For the astrocytes, it is interesting that BCP stimulated cell
proliferation at a concentration lower than 1.0 × 10−6M and
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Figure 4: IR spectra of (from top to bottom) pure BCP, pure DHA,
mixture BCP70%-DHA30%, BCP52%-DHA48%, andmathematical
sum of the IR spectra of the two pure components (BCP and DHA).
that this activity increased with decreasing concentrations.
All toxic effects disappeared in the BCP+DHA mixture
(Figure 5(c)). DHA did not have a toxic effect on either the
fibroblasts or the astrocytes at any of the concentrations
(Figure 5(b)). Hence, the disappearance of the toxic effect of
BCP can be attributed to the simultaneous presence in solu-
tion of DHA, although the presence of DHA also seemed to
decrease the BCP stimulation of astrocyte proliferation (this
occurred starting from a BCP concentration of 1.0 × 10−6M,
as shown in Figure 5(c)).
3.3. In Vivo Study. Theanimals showed no sign of discomfort
during any of the experimental phases. Food was consumed
regularly and body weight increased similarly in all groups.
The per os procedure was carried out easily in all groups.
3.3.1. Analgesimeter Test. This test was carried out to evaluate
the effect of one and two weeks of BCP and BCP+DHA
treatment on the mechanical paw-withdrawal threshold with
respect to basal conditions (Analg 1). One-way ANOVA
applied to the percentage of variation of latency recorded
during the second and third tests with respect to the first one
revealed different effects of the treatments, while BCP alone
always resulted in higher values, that is, analgesia, BCP+DHA
tended to produce lower (hyperalgesic) levels. In particular,
there was a significant effect of treatment during the second
test (Analg 2) for the right (treated) paw (𝐹
2,17
= 4.25; 𝑃 <
0.03) due to the significant difference between the BCP and
BCP+DHA groups (Figure 6).
3.3.2. Formalin Test. During the formalin test, both spon-
taneous behaviour and formalin-induced responses were
measured and quantified for comparisons.
Spontaneous Behaviour. ANOVA applied to the spontaneous
behaviour and body weight recorded along the experimental
sessions did not show significant differences among groups;
hence, the results are not shown.
Pain Responses. When treated with formalin and placed in
the experimental apparatus, all animals showed characteristic
behavioural responses present in the formalin test: licking,
flexing, and paw jerk. As expected, these responses showed
a biphasic time course characterized by an initial burst of
pain behaviour (first phase, 0–5min) followed by an inter-
mediate phase with a drastic decrease of all pain responses
(interphase, 5–20min) and the second phase (20–60min) in
which inflammatory events certainly play the major role.
Analysis of the Differences among Groups in Each Test
Formalin Test 1 (FT1). During this test, data were collected
only to evaluate the effect of treatment with respect to basal
conditions. After this test, animals belonging to the same cage
were randomly assigned to one of the three experimental
groups.
Formalin Test 2 (FT2)
Flexing. One-way ANOVA applied to flexing duration
revealed a significant effect of Treatment (𝐹
2,220
= 18.26; 𝑃 <
0.001) due to the significantly lower levels in the BCP and
BCP+DHA groups (𝑃 < 0.0001 for both) with respect to the
OIL group. In particular, the interaction Treatment × Time
(𝐹
22,220
= 3.8; 𝑃 < 0.001) showed that the reduction of the
formalin-induced flexing of the paw was due to the lower
levels from 30 to 45min of FT2 with respect to OIL-treated
animals (𝑃 < 0.01 for BCP and 𝑃 < 0.05 for BCP+DHA)
(Figure 7(a)).
Licking. One-way ANOVA also showed a significant effect of
Treatment on licking duration (𝐹
2,220
= 11.19;𝑃 < 0.001) due
to the lower levels in the BCP and BCP+DHA groups than in
the OIL group (𝑃 < 0.001 and 𝑃 < 0.002, resp.). In particular,
the Treatment × Time interaction (𝐹
22,220
= 1.78; 𝑃 < 0.019)
showed that significant differences between the OIL and the
treated groups were already present during the first phase and
the early second phase (20–35min), as shown in Figure 7(b).
Paw Jerk. ANOVA applied to paw jerk frequency revealed a
significant effect of Treatment (𝐹
2,220
= 9.12; 𝑃 < 0.001)
due to lower levels in the BCP group than in the OIL group
(𝑃 < 0.001). In particular, the Treatment × Time interaction
(𝐹
22,220
= 1.57; 𝑃 < 0.05) showed a reduction of formalin-
induced jerking of the paw by both substances during the
second phase (in the 30–35min interval) of FT2 with respect
to OIL-treated animals (𝑃 < 0.05 for both treatments)
(Figure 7(c)).
Formalin Test 3 (FT3)
Flexing. ANOVA showed a significant effect of Treatment on
flexing duration (𝐹
2,220
= 5.896; 𝑃 < 0.009) due to the lower
levels in the BCP group than in the OI L group (𝑃 < 0.002).
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Figure 5: Viability of fibroblasts (NIH3T3) and astrocytes (U373-MG) after 24 hours of contact with different concentrations of BCP (a),
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Moreover, as shown in Figure 7(d), the significant Treatment
× Time interaction (𝐹
22,220
= 2.12; 𝑃 < 0.003) was due to a
reduction of formalin-induced flexing in the BCP group in
the 30–40min interval of the test with respect to OIL-treated
animals (𝑃 < 0.05 for both intervals).
Licking. ANOVA revealed a significant effect of Treatment on
licking (𝐹
2,220
= 11.12; 𝑃 < 0.0005) due to lower levels in BCP
and BCP+DHA animals than in the OIL group (𝑃 < 0.001
and 𝑃 < 0.001, resp.) (Figure 7(e)).
Paw Jerk. ANOVA applied to paw jerk frequency showed a
significant effect of Treatment (𝐹
2,220
= 4.73; 𝑃 < 0.02) due
to the lower levels in the BCP group than in the OIL group
(𝑃 < 0.005) (Figure 7(f)).
Analysis of the Differences within Groups in theThree Tests. To
evaluate the effects of treatments on the modulation of pain
responses during the repeated formalin tests, ANOVA was
applied to flexing, licking, and paw jerk recorded during FT1,
FT2, and FT3with the factorsGroup andTest.The cumulative
sum of each behavioural response during the early second
phase (20–45min) was chosen as the most representative of
the treatment effects.
Flexing. Two-way ANOVA revealed a significant effect of
Treatment (𝐹
2,62
= 12.25; 𝑃 < 0.001), Test (𝐹
2,62
= 18.92;
𝑃 < 0.001), and the Treatment × Test interaction (𝐹
4,62
=
3.63; 𝑃 < 0.01). As shown in Figure 8(a), this was due to the
reduction of formalin-induced flexing in the BCP group in
FT2 and FT3 with respect to FT1 (𝑃 < 0.001 for both). In
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Figure 9: Testosterone and estradiol plasma levels determined at
the end of the experimental sessions in OIL (white), BCP (light
gray), and BCP+DHA (dark gray) groups. BCP administration for
two weeks significantly increased E and T plasma levels, whereas
BCP+DHA completely reversed this increase. Histograms represent
means ± SEM. Estradiol: ∗𝑃 < 0.04 versus OIL and #𝑃 < 0.03 versus
BCP+DHA. Testosterone: ∗𝑃 < 0.03 versus OIL and #𝑃 < 0.04
versus BCP+DHA.
the BCP+DHA group, flexing duration was decreased in FT2
and FT3 with respect to FT1 (𝑃 < 0.0001 and 𝑃 < 0.002,
resp.) but was lower than in the OIL group only during FT3
(𝑃 < 0.002).
Licking. Two-way ANOVA showed only a significant effect
of Treatment (𝐹
2,62
= 4.53; 𝑃 < 0.014) due to the lower
levels in the BCP group than in the OIL group (𝑃 < 0.005)
(Figure 8(b)).
Paw Jerk. Two-way ANOVA revealed a significant effect of
Treatment (𝐹
2,62
= 6.34; 𝑃 < 0.003), due to the lower levels
in the BCP and BCP+DHA groups (𝑃 < 0.003 for both)
and of Test (𝐹
2,62
= 13.05; 𝑃 < 0.001) due to the lower levels
in FT2 and FT3 with respect to FT1 (𝑃 < 0.001 for both)
(Figure 8(c)).
Estradiol (E) and Testosterone (T) Plasma Levels. The effect of
treatments on E and T plasma levels was examined at the end
of the experiment. One-way ANOVA showed a significant
effect of treatment on the E and T levels (𝐹
2,14
= 3.78, 𝑃 =
0.048 and𝐹
2,14
= 3.76,𝑃 = 0.049, resp.). As shown in Figure 9,
BCP treatment significantly increased E and T plasma levels
(𝑃 < 0.04 and 𝑃 < 0.026, resp.), while there were no changes
in these hormones in the BCP+DHA group. In particular, T
levels were 90% higher and E more than 150% higher in the
BCP group than in the OIL and BCP+DHA groups.
4. Discussion
The main result of the present experiment is the strong
analgesic effect recorded in animals treated with BCP and
BCP+DHA in a model of persistent pain. Indeed, BCP alone
or in combination with DHA resulted in a marked reduction
of formalin-induced pain responses.
Chronic pain is a debilitating disease characterized
most of the time by inflammatory processes underlying the
main disease. This results in serious personal and social
costs which pharmaceutical companies are addressing by
producing synthetic or semisynthetic products. First-line
pharmacological treatments for chronic pain include opioid
and nonsteroidal anti-inflammatory drugs (NSAIDs), both of
which are associated with serious side effects; for example,
we have repeatedly found hypogonadism in association with
opioid use [21, 22]. Therefore, there is the need for new
pharmacological approaches that curtail the progression of
the disease and reduce the pain but do not produce side
effects. The “new” substances to be considered are mostly
plant extracts, popularly known as natural analgesics. These
compounds, essential oils including hundreds of elements or
their extracts, offer great hope for the treatment of painful
syndromes like fibromyalgia, low back pain, and muscu-
loskeletal disorders, all of which present multiple symptoms
often of multiple origin. Hence, it is imperative to carry out
experiments able to clarify their effects. Another important
aspect to be considered in the choice of these substances is
that chronic pain is commonly associated with other med-
ical conditions like depression, anxiety, insomnia, chronic
fatigue, diabetes, cancer, and neurological dysfunctions, all
requiring treatments that often add their side effects to those
of the pain killers. These pathological aspects might also be
significantly modulated by essential oil components.
In the present study, we have shown that 𝛽-caryophyllene
(BCP) decreases pain with a long-term effect and without
any apparent side effect. BCP, a common sesquiterpene
present in cannabis and in many other plants, is a potent
CB2 agonist producing peripheral antinociception [16, 23–
25] without the central nervous system effects mediated by
CB1 receptors [23, 26]. Therefore, the selective activation of
CB2 receptors may produce peripheral pain relief without
CNS psychotropic effects. BCP was effective in reducing
neuropathic pain, in a CB2 receptor-dependent manner [27],
and osteoporosis [5], and it prevented experimental colitis by
reducing inflammation [28].
DHA belongs to the omega-3 family and has strong
antioxidant and anti-inflammatory properties [29]. Our deci-
sion to use DHA instead of EPA was based on numerous
studies suggesting that DHA is more useful than EPA. It
has been shown that most of the neuroprotective effects
of omega-3 oils are derived from the DHA component
rather than the EPA component [30]. DHA also increases
lipoxins, inhibits NFkb, and produces neuroprotectin-D and
resolvins, which are important for complete resolution of the
inflammatory process [31]; it is important to underline that
the incomplete resolution of an inflammatory response can be
a significant contributor to chronic and exacerbating disease
and pain development.
Our in vitro acute toxicity tests indicated that BCP
was toxic at high concentration, whereas its toxicity was
completely reversed by concomitant DHA administration.
Therefore, in vivo BCP analgesic activity was tested alone
or in combination with DHA at half concentration. To
model a clinical situation of persistent inflammation, we used
repeated administration of a low concentration of formalin as
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Figure 10: Failure of timely resolution of inflammation drives chronic inflammatory conditions and pain. Resolution of inflammation requires
the elimination of key inflammatory cells and the downregulation of proinflammatory mediators at the inflamed sites. Docosahexaenoic acid
(DHA) is converted into resolvins and protectins that counteract excessive inflammatory responses and stimulate proresolving mechanisms,
tissue repair, and decreased pain. Beta-caryophyllene (BCP) reduces inflammation by its action on CB2 receptors, which aremostly expressed
on immune cells and microglia.
irritant and BCP+DHA combinations were administered for
two weeks. The formalin test was used because it allows pain
intensity determination without any external interference.
When injected in the paw, the irritant induces pain responses
that can easily be quantified. In our laboratory, we determine
each behaviour singly, that is, licking, flexing, or jerking
of the injected paw [32], and thus it is possible to study
the modulation of each neural circuit. Indeed, while paw
jerk is mostly spinal cord mediated, licking and flexing are
more complex responses involving longer subcortical reflex
circuits. The general modulation of all three pain responses
observed in the present study suggested general analgesia,
probably due to attenuation of the peripheral inflammation.
These results are in agreement with other studies reporting
that BCP has analgesic and anti-inflammatory effects in both
rats and mice [15, 16].
At present, we have no clear hypothesis concerning the
interesting BCP+DHA synergistic activity. However, it is
very likely that both substances show competitive bind-
ing/interaction for the same receptor since the modulation
was also present in the in vitro experiment, in which the
results cannot be explained by systemic effects.
Because of the endocrinopathies often observed in
chronic pain patients, we collected blood samples at the
end of the last formalin test to measure the testosterone (T)
and estradiol (E) plasma levels in all experimental groups.
These hormones were determined to study the possible
modulatory effects of the tested substances upon the HPG
axis or other related endocrine sites. The administration of
BCP alone increased both the T and E plasma levels, while
the combination of BCP at lower dose plus DHA did not
change the hormonal plasma levels. Testosterone is decreased
by pain as well as by pain killers [33], with a high number
of sequelae that significantly decrease the quality of life in
these patients. Our BCP+DHA treatment did not induce
any decrease in the gonadal hormone levels. Moreover, in
agreement with other experimental results by our group
and others [32, 34], we have to consider the possibility that
the analgesia could be testosterone-mediated. An interesting
hypothesis is that higher levels of T and E may be involved
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in the observed analgesia via suppression of glial activity
[35], since it has been shown that glial cells produce many
inflammatory mediators leading to abnormal pain [36].
In conclusion, the results of our experiment confirm
the potent analgesic role of these compounds and their
synergistic action and suggest their possible use in long-
lasting treatments (Figure 10).
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